Amneal Pharmaceuticals reported results for the quarter ended 2026 with revenue of $796.2M and diluted EPS of $0.18, versus $724.51M and $0.07 in the prior-year quarter, as net income rose to $57.66M from $22.42M a year earlier.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$796.2M$724.51M9.9% | Net income²$57.66M$22.42M157.2% | Diluted EPS³$0.18$0.07157.1% |
¹ Reported as “Net revenue”. ² Reported as “Net income attributable to Amneal Pharmaceuticals, Inc.”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by higher volumes and new product launches, with consolidated net revenue rising about 7–10% year over year (Q2 +9.9%, H1 +7.0%).
- Channel shifts included a decline in low‑margin AvKARE distribution sales, which was partly offset by expansion in government label channels and new product introductions.
- Specialty brands CREXONT®, BREKIYA® autoinjector, and UNITHROID® posted strong sales gains, contributing to segment growth.
- Affordable Medicines benefited from new launches and demand in women’s health and ADHD, with improved gross margins from mix and scale.
- Operational items: the company agreed to acquire Kashiv (cash, stock and contingent payments) pending close in Q3; water damage at an India facility may affect second-half production and profitability.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.